Diplomats: Iran shrouds suspected nuclear site

VIENNA (AP) ? Iran has shrouded a building that the U.N. nuclear agency suspects was used for secret work on atomic weapons, meaning spy satellites can no longer monitor Tehran's alleged efforts to clean up the site, diplomats told The Associated Press on Friday.

For months, satellite images have recorded what the International Atomic Energy Agency suspects is an attempt to sanitize the site. At the same time, Iran has repeatedly rebuffed agency efforts for access ? and did so again Friday. Talks between the two sides ended without an agreement that would have allowed IAEA experts to visit the site at the Parchin military complex southeast of Tehran.

The diplomats said the main building is now covered with what appears to be plastic sheeting, shielding any activity there from the outside world and effectively shutting down the IAEA's only way of monitoring the site with its eyes in the sky through spy and commercial satellite imagery.

Iran denies any cover-up at Parchin or anywhere else, describing allegations that it worked secretly on developing nuclear arms as lies based on fabricated intelligence made available to the agency by the U.S., its Western allies and Israel. It also denies that its public nuclear work ? uranium enrichment ? is meant to create nuclear missile warheads, saying it is enriching only to make reactor fuel, medical isotopes and for research.

But it has refused eight months of agency requests to visit Parchin and has turned away IAEA attempts to probe other alleged weapons research and development for over four years, as well as rejecting offers of enriched reactor fuel from abroad. Its defiance has heightened suspicions about its ultimate nuclear aims, led to U.N. and other multinational sanctions, and increased threats of armed action from Israel, which says it will never accept an Iran armed with atomic weapons.

Israel is particularly worried about a fortified bunker at Fordo, where Iran has begun producing uranium enriched to a level closer to the grade used in nuclear weapons than its main stockpile of fuel grade material. About 70 kilometers (40 miles) south of Tehran, Fordo has about 800 centrifuges operating so far, enriching to a 20-percent level, and continues assembling others without operating them ? diplomats say that close to 3,000 are now fully or partially screwed together, including hundreds over the past three months.

Possibly alluding to such work, Israeli Prime Minister Benjamin Netanyahu said Friday that his country has recently received "additional proof of the fact that Iran is continuing to make accelerated progress toward achieving nuclear weapons while totally ignoring international demands."

Parchin is an important piece of Iran's suspected nuclear puzzle of secret atomic weapons research and development. The agency believes Iran ran explosive tests in 2003 needed to set off a nuclear charge there, with the suspected blasts taking place inside a pressure chamber.

Iran has never said whether the chamber existed, but describes Parchin as a conventional military site ? and has kept IAEA inspectors from visiting until there is agreement on a road map of procedures on how such an inspection can take place.

IAEA officials have suggested that this caveat is a stalling tactic, allowing for removal of all traces of such suspected work ? and over the past half year have shown the agency's 35-board nation members satellite photos documenting what they say is an extensive cleanup of the site.

Diplomats inside those closed briefings have described the images showing earth moving equipment around the buildings, streams of water pouring out of the site where the chamber is believed to be, and the demolition of surrounding structures. Earlier this year, IAEA chief Yukiya Amano suggested that any visit by his inspectors had to come sooner than later if they hoped to find any evidence that was left by the alleged cleanup.

Iran's refusal to give access had left the agency no choice but to rely solely on satellite views ? until the shrouding went up and the curtain was dropped on what, if any, cleaning up was continuing at the site. The diplomats said the buildings were covered less than two weeks ago. They demanded anonymity because they weren't authorized to divulge information meant to be kept confidential within the agency.

The diplomats' accounts appeared to be backed up by a satellite image dated Aug. 15 and published Friday by the Institute for Science and International Security, showing what the Washington-based think tank said appeared "to be pink tent-like material" over the building allegedly housing the explosives chamber and an adjacent building.

"The purpose of covering the buildings could be to conceal further cleanup activity from overhead satellites or to contain the activity inside," ISIS said in a commentary accompanying the photos

Expectations for Friday's meeting had been modest from the outset and Herman Nackaerts, the chief IAEA negotiator at the talks, said "important differences ... prevented agreement."

Iranian envoy Ali Asghar Soltanieh was more upbeat, telling reporters "there are still some differences... but I have to say we are moving forward."

The information on the shrouding of the building came from two diplomats who demanded anonymity because they were not authorized to discuss the confidential satellite images. One of the two, who was familiar with the outcome of Friday's talks, questioned Soltanieh's comments, saying that little progress was made on the main issue of contention ? demands by Iranians that were refused by the agency that any access to Parchin, or other sites, officials and documents the IAEA is interested in be carefully orchestrated by specifying who or what can be accessed and how often.

IAEA officials say that would give the agency little leeway to follow up on any new evidence it finds by effectively denying them a chance to revisit sites, again question officials or asking for new documentation.

___

Ian Deitch contributed to this story from Jerusalem

Source: http://news.yahoo.com/diplomats-iran-shrouds-suspected-nuclear-193620813.html

george washington russell westbrook horsetail falls ice t downton abbey new york knicks president day

Small business Advertising and marketing On the internet | Contacts ...

Several persons are beginning On-line Corporations, but learning on the fly, so to speak, how you can get traffic to their web sites. A huge aspect to be considered is how much will it price to obtain the website traffic to your internet site. I lately wrote two articles, 1 about specific landing pages along with the second about matching keyword phrases to distinct landing pages. This time I?m going to cover the price of each and every keyword. In other words just how much really should you pay for every phrase or keyword

You?ll be able to recognize the demand for on the net business enterprise by hunting in the searches made on the search engines like google. They?re phrases like business conferencing meeting on the net net, advertising small business on the net web, company cost-free on line web-site internet, on line internet enterprise chance, organization hosting on line page internet, on the web business net hosting and business enterprise generate online site internet chance just to mention several.

There is a lot that?s to become learned about this topic and I?m only going to scratch the surface in this article, however it need to get you began off correctly. There are lots of components to think about that will make a massive difference within your profit.

You need to ensure that you have a various landing page on your web-site for every single location of you organization. By way of example on my web-site I have a landing page for Work At House, Top ten small business, Household Based Enterprise, Moms Jobs, Affiliates, Data Entry, Online Paid Surveys as well as a link to my real time newsletter.

If you are utilizing one of the tools accessible to us named (PPC) Paid Per Click Advertising, whereby we spend a search engine pennies to show our ad when a person types in specific keyword. As I talked about in my other article you should break up your keywords in such a manner as to possess all your keywords and phrases on a given subject sent to the specific landing page. For instance you should have all Perform At House keywords and phrases visit your landing page, that is largely about Work At House suggestions. Like wise have you keywords and phrases on Household Based Business go to the landing page that highlights Property Based Organization Opportunities.

Additionally you do not choose to bidding against your self so you wish to make sure that you don?t mix and match your key phrases. You will want to advertise only the key phrases that match a certain landing page when using (PPC) Paid Per Click Advertising. Don?t have Work At House keywords mixed in with On the web Paid Surveys sending people to many landing Pages.

You might need to use multiple variation of a given keyword. Feel concerning the conversation going on in your customer?s head. What would you kind in in case you were searching for the same thing What would other people sort Do not just set you campaigns to run on a maximum value per click. Do some investigation to see just how much a particular keyword is becoming searched for. If it?s not one of the most well-known reduce you bid quantity. When you have got performed this monitor it more than a couple of weeks or perhaps a month so you?ll be able to see when you receiving the identical amount of clicks. Search engines usually are not normally going to provide you the ideal price. A few of the big ones are fairly fair, but I want manage of those factors myself. A lot of of my key phrases are half the price of a few of the big ones. Prior to I learned this though, several search engines like google had been charging me full price tag when it was not warranted.

Each and every subtle change within your internet site landing page, keywords and phrases, keyword bidding, regardless of how minuscule, has an impact on your consumer. I generally advocate adjust, monitor, analyze, modify and preserve continuing the procedure. Compare the new adjust to the old 1 to ensure that you are able to see which landing page converts finest.

As soon as you?ve got had your web-site going for awhile there?s constantly far more fine tuning to accomplish.

Please really feel totally free to read far more of this article by visiting my link in the resource box below. I often get pleasure from getting emails pertaining to my articles or my site. Your feedback is essential to me.

Own inexpensiverayban sunglasses from certified rayban Store immediately with Fast Shipping and delivery, Safe and sound Payment & Superb Customer Satisfaction from us.

Source: http://blog.1stfind.com/?p=482612&utm_source=rss&utm_medium=rss&utm_campaign=small-business-advertising-and-marketing-on-the-internet

duggar family gilbert arenas dexter dexter facebook timeline kim jong il kim jong il

Video: How could Tropical Storm Isaac affect the convention? (cbsnews)

Share With Friends: | | Politics - Top Stories Stories, RSS and RSS Feed via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/243227538?client_source=feed&format=rss

crimson tide dixville notch 2013 ford fusion lsu football lsu football bcs jay z glory

There's Something Wrong With Joseph Gordon-Levitt In Dailies!

The new poster for "Looper" is kind of like a more badass version of Marty McFly fading out of the Polaroid in "Back in the Future," but with hitmen. Also, Brad Pitt kills them softly, and Aaron Burr gets his redemption in today's Dailies! » This short film "Aaron Burr, Part 2" examines the true [...]

Source: http://moviesblog.mtv.com/2012/08/23/looper-poster-dailies-2/

times square 2012 predictions new years eve ball drop new years eve times square 2012 2012 holidays prosperity japan earthquake

Alzheimer's drug fails study but flashes potential

INDIANAPOLIS (AP) ? An Alzheimer's treatment from Eli Lilly and Co. failed to slow memory decline in two separate patient studies, but the drug did show some potential to help in mild cases of the mind-robbing condition that is notoriously difficult to treat.

The Indianapolis drugmaker's announcement could be a step toward a long-awaited breakthrough in the fight against the disease. But researchers not tied to the studies ? and Eli Lilly itself ? cautioned against overreacting to the initial results.

Lilly said Friday that its treatment, solanezumab, failed to slow the rate of cognitive decline, which involves a person's ability to remember things, in two late-stage studies of about 1,000 patients each. But when data from the trials were combined, scientists saw a statistically significant slowing of that rate in the bigger population.

They also saw a statistically significant result when they examined a subgroup of patients with mild cases of Alzheimer's disease. The studies focused on patients with mild to moderate Alzheimer's cases.

Lilly officials would not discuss details of the results and said that they plan to talk with regulators about the next steps for the drug, which has yet to receive Food and Drug Administration approval. Full results from the studies will be presented at two scientific conferences in October. It's unclear how the FDA will view the results, given that the drug missed its main goals.

William H Thies, chief medical and scientific officer for the Alzheimer's Association, which was not involved in Lilly's research, said the statistical significance of the combined results is important.

"If that can be replicated, that is a major finding," he said. "It's the first time we've been able to change the course of Alzheimer's disease or any part of Alzheimer's disease in people."

But because the drug missed its main goals, Thies said the drug "isn't going to the (FDA) tomorrow to be approved for sale."

If you look through "rose-colored glasses" at the results, there may be a sign of potential benefit on cognitive tests, said Dr. Ronald Petersen, director of the Mayo Clinic's Alzheimer's Disease Research Center. But it is not clear whether that is enough to make a real difference clinically in how patients do, he said.

The key will be details the company will present later on brain imaging and other tests, he said.

"The danger would be an over-interpretation of a small finding or a subtle effect," said Petersen, who heads a safety monitoring panel for two companies working on a different Alzheimer's treatment.

About 35 million people worldwide have dementia, a term for brain disorders that affect memory, judgment and other mental functions. Alzheimer's is the most common type. In the United States, more than 5 million people have Alzheimer's, which is the country's sixth-leading cause of death.

Many Alzheimer's patients typically live four to eight years after diagnosis, as the disease gradually erodes their memory and ability to think or perform simple tasks. Current Alzheimer's treatments only temporarily ease symptoms such as memory loss, confusion and agitation. They don't slow, stop or reverse mental decline.

Drugmakers have tried and failed for years to develop successful treatments for the disease, and patients and doctors are anxious for something that can slow the disease's progression. Analysts have said such a treatment, if approved, could be worth billions of dollars in sales.

Earlier this month, Pfizer Inc. and Johnson & Johnson said they would end development of an intravenous version of their potential Alzheimer's treatment, bapineuzumab, after two late-stage studies showed it worked no better than a placebo in patients with mild-to-moderate cases. The companies are still studying an injectable version of the drug.

Lilly's announcement Friday comes two years after the drugmaker stopped developing another potential treatment, semagacestat, after patients taking the drug wound up faring worse than those on a placebo.

Scientists say the search for a better Alzheimer's treatment presents several problems. To start, the brain is the most complex organ in the body and the one that researchers know the least about.

Biological triggers behind disease development remain largely unproven, although certain factors like age increase the risk of getting it. Scientists believe changes in the brain of a person with Alzheimer's begin several years before the patient shows symptoms of the disease. That means that by the time diagnosis happens, the brain may be essentially too damaged for potential treatments to work.

Doctors diagnosed John Baker, 71, of Watertown, S.D., with early-stage Alzheimer's disease in 2010. The former mechanical engineer said his family has watched him become forgetful, tell the same stories over and over and misplace things. He said he has no expectation that scientists will make a breakthrough soon enough to help him.

"Realistically, I'm not going to wait and worry and read every line on every report," he said.

Still, he's taking Aricept, a treatment for the disease made by Pfizer and Japanese company Esai Co. Ltd, to try to control the symptoms. He's also participating in a brain scan study to help doctors find a cure for future generations.

Lilly officials cautioned Friday that their study did not show that solanezumab slowed the progression of Alzheimer's. Even so, they were encouraged.

Solanezumab binds to beta-amyloid protein, which scientists believe is a key component to sticky plaque that basically gums up the brain of a patient with Alzheimer's disease. The drug is designed to bind to the protein and help the body remove it from the brain before it can form that plaque. Lilly said that while the individual trials missed their main goals, the combined results showed there may be some validity to this approach.

"We really think this idea of attacking amyloid plaques is a valid hypothesis, that's important news," said Dave Ricks, president of Lilly Bio-Medicines.

But Dr. Sam Gandy, head of Alzheimer's disease research at Mount Sinai School of Medicine in New York, said Lilly's statement on the results "is very tentative."

"I believe in the notion that an amyloid-lowering agent like solanezumab will eventually work in early disease or pre-symptomatically, but whether these data provide compelling evidence that solanezumab has 'cleared the bar' just cannot be concluded" until full results are presented, Gandy wrote in an email.

Dr. Tim Anderson, an analyst who covers Lilly for Bernstein Research, said in a research note the solanezumab results would be viewed positively because expectations for the drug were low.

Lilly is counting on drugs in its development pipeline to help replace revenue it is losing due to patent expirations for key products. The company lost U.S. patent protection for its all-time best-selling drug, the antipsychotic Zyprexa, last year, and it will lose protection for its current top-seller, the antidepressant Cymbalta, next year. Those drugs totaled $8.78 billion in revenue last year, or 36 percent of the company's total.

Lilly shares climbed 3.4 percent, or $1.46, to $43.86 Friday, outpacing broader trading indexes that rose less than 1 percent.

___

AP Chief Medical Writer Marilynn Marchione in Milwaukee contributed to this report.

Source: http://news.yahoo.com/alzheimers-drug-fails-study-flashes-potential-163148666--finance.html

nfl playoff picture rose bowl 2012 sat cheating scandal hangover cure lebron james engaged auld lang syne end of the world 2012

China reveals big debt fear with rescue of tiny firm

A portrait of former Chinese leader Mao Zedong on a yuan banknote is reflected in water droplets in this photo illustration taken in Taipei in this October 8, 2010 file photo. ? Reuters pic

SHANGHAI, Aug 24 ? China's eastern province of Zhejiang has launched an extraordinary campaign to rescue a small, indebted packaging firm to prevent a wave of regional insolvencies, a sign of what experts fear is a debt crisis stalking the country's companies.

Zhejiang's Pujiang county, south of Shanghai, sprang to the rescue of privately owned Pujiang Hongye Ltd Co this week, worried its financial collapse could send other local businesses under. The company, with just 200 workers, had not only borrowed heavily; it had also helped provide credit to other firms, local government sources and a news report said.

Pujiang Hongye guaranteed millions of dollars in loans for other businesses, a county government source said ? just one tiny part of a barely visible web of guarantees that has spread quickly across China due to Beijing's efforts to stimulate credit to smaller enterprises, the backbone of China's economy.

?Right now the government just wants to help this business restart production,? a separate source, a county government official, said when asked about local media reports that the county had made an arrangement with Pujiang Hongye's owner, Pan Shaojiang, to keep the business running and avoid default.

The official, who declined to be named because he was not authorised speak publicly to foreign media, would not give details on the arrangement but said a recent report in a local newspaper, China Enterprise News, had given a broadly accurate description of the situation so far.

According to this report, Pan closed his firm's production line, unable to pay his debts or stand behind his guarantees, and left for Dubai in July amid allegations he had shifted company assets to family members. Ordinarily, a small firm with so few workers would have been allowed to collapse.

But China Enterprise News said the county instead convinced Pan to return and restart his business, with local police making a public statement that he would not be prosecuted.

The county official said he could not confirm the allegations about Pan's asset transfers.

Pan could not be reached for comment.

Hidden problem

The proliferation of loan guarantees follows Beijing's drive to throw loan lifelines to China's legions of small and medium-sized businesses (SMEs), which account for around 60 per cent of China's economy, pay half of its taxes and hire eight out of 10 of its workers, and yet are struggling to stay afloat as growth slows.

There are no publicly available figures on the extent of third-party guarantees in China ? those made by non-financial firms for other, unrelated companies ? but economists believe they are now widespread in the SME sector.

They point to the well-known popularity of such guarantees as a financing tool among China's larger borrowers, for whom more data is available. Last year, a survey of 499 Chinese bond issuers by HSBC's research department found 41 per cent of issuers had provided guarantees to external parties.

?It's very unusual to have an essentially unrelated third party be a guarantor on loans, but it is common in China,? said James Antos, banking analyst at Mizuho Securities in Hong Kong.

The guarantee system allows banks to lend to smaller, riskier clients provided they can find a third-party guarantor who will repay the loan if the borrower defaults.

This helps small companies stay solvent and allows state-controlled banks to meet their policy targets, but economists fear such guarantees can spread risk instead of prevent it.

Third-party guarantees have flourished as China's economy has slowed, helping small, struggling firms secure bank loans that would otherwise have been denied. But economists fear many of the guarantees are not worth the paper they are written on.

Even professional credit-guarantee firms, which offer higher-quality assurances to lenders compared with third-party guarantors, are showing signs of trouble: almost half of Beijing's 134 credit-guarantee firms lost money in the first half of 2012, according to Beijing Guarantee Association data.

Amplifying risk

Stephen Green, senior economist at Standard Chartered, has said the guarantee system is now ?operating in reverse, amplifying risk rather than dispersing and controlling risk?.

?The failure of one company sets off a chain reaction of insolvencies as a guarantee is called, causing other guarantees to be triggered,? he wrote in a research note last week.

In a sign of the official concern over indebtedness among smaller firms, Shanghai Vice Mayor Tu Guangshao was quoted by the official Shanghai Daily yesterday as encouraging lenders to increase their tolerance for bad loans incurred by SMEs.

He said Shanghai's recently unveiled 1 billion yuan stimulus package was designed to encourage banks to write more risky loans to smaller enterprises.

Green of Standard Chartered said banks should check that a guarantor has not pledged the same assets to other lenders, but this could be difficult ? especially if the guarantor has taken out its own informal high-interest loans, as Pujiang Hongye is reported to have done, or made informal loans to other firms.

?It only takes a single bad loan to wipe out their capital and ruin the usefulness of all their other guarantees,? he wrote.

Frances Cheung, fixed income strategist at Credit Agricole CIB, said policy changes giving SMEs more access to high-yield bond markets should reduce their dependence on loan guarantees, but that the situation ?warrants closer monitoring?.

?Should the liquidity or even solvency problem among local corporates intensify, there would be a knock-on impact on local government and banks as well,? Cheung said.

A person who answered the phone at Pujiang Hongye declined to respond to questions about the company's current financial condition, but said that it had resumed operations.

By resuming production and sales, Pujiang Hongye has avoided immediate default on 316 million yuan (RM150 million) in liabilities, made up of 82 million yuan in bank loans, 80 million yuan owed to informal high-interest lenders and 154 million yuan in third-party loan guarantees, the China Enterprise News newspaper said, citing information provided by its creditors. ? Reuters?

?

Source: http://business.rss.themalaysianinsider.com/c/33362/f/567636/s/22ae0a22/l/0L0Sthemalaysianinsider0N0Cbusiness0Carticle0Cchina0Ereveals0Ebig0Edebt0Efear0Ewith0Erescue0Eof0Etiny0Efirm0C/story01.htm

stephen hill draft tracker the pirates band of misfits cleveland browns minnesota twins green bay packers bobby abreu

Complete Guidelines to Health and Fitness: LATISSE? - New ...

Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug
Administration (FDA) has approved LATISSE? (bimatoprost ophthalmic
solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.
Eyelash hypotrichosis is another name for having inadequate or not
enough eyelashes. LATISSE? is the first and only science-based treatment
approved by the FDA to enhance eyelash prominence as measured by
increases in length, thickness and darkness of eyelashes.

"LATISSE? fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the FDA that increases the growth of eyelashes, making them longer, thicker and darker," said Scott Whitcup, M.D., Allergan's Executive Vice President of Research and Development. "As the global leader in medical aesthetics, LATISSE? exemplifies our continuing commitment to developing innovative treatments that are studied in well-controlled clinical trials, manufactured to pharmaceutical standards, appropriately labeled for use, and available to consumers as a prescription product."

Available only through a doctor, LATISSE? is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. LATISSE? users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain effect, continued treatment with LATISSE? is required. If use of LATISSE? is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).

Similar to Allergan's other medical aesthetic offerings, the benefits of LATISSE? are derived from scientific evidence, its quality formulation, and medical origin. LATISSE? was clinically tested in a pivotal Phase III, multi-center, double-masked, placebo-controlled study to assess its safety and efficacy in which all endpoints (improved eyelash prominence, length, thickness and darkness) were met. In addition, like BOTOX? (botulinum toxin type A), which was first approved by the FDA as a medical treatment for eye disorders and was later found to have an aesthetic benefit, bimatoprost, the active ingredient in LATISSE?, was first approved in 2001 as a medical product to lower intraocular pressure in people with open-angle glaucoma or ocular hypertension. Patients treated with bimatoprost for this specific eye condition experienced eyelash growth as a side effect. The long-term safety of bimatoprost for therapeutic use has been recognized by the medical community and well established based on use in 32 clinical trials involving more than 5,700 glaucoma patients and more than 13 years of clinical trial experience. Given the existing and substantial clinical and post-marketing safety data with bimatoprost solution 0.03%, coupled with the positive results from the Phase III LATISSE? study, LATISSE? provides patients a clinically meaningful aesthetic benefit with a favorable safety profile.

Bimatoprost is the active pharmaceutical ingredient in the formulation of LATISSE? and is a structural prostaglandin analog, a lipid compound derived from fatty acids designed to bind to prostaglandin (PG) receptors. PG receptors are present in hair, particularly in the dermal papilla and outer root sheath. Although the precise mechanism of action is unknown, PG receptors are thought to be involved in the development and regrowth of the hair follicle,1 by increasing the percent of hairs in, and the duration of, the anagen or growth phase.

"As an oculoplastic surgeon who has treated both medical eye conditions as well as aesthetic needs, I have extensive knowledge of and experience with the established therapeutic safety profile for bimatoprost," said Steven Fagien, M.D., F.A.C.S., in private practice at Aesthetic Eyelid Plastic Surgery in Boca Raton, Florida, and LATISSE? clinical investigator. "In the clinical study with LATISSE?, I observed statistically significant differences in eyelash growth and resulting patient satisfaction. Now that LATISSE? is FDA approved, I look forward to prescribing it to my patients who will enjoy the benefits of more prominent eyelashes while I remain confident in the treatment's favorable safety profile."

LATISSE? will be available in the United States by prescription only and is subject to all U.S. guidelines applicable to dispensing a prescription product. Based on today's FDA approval, Allergan expects to launch the product nationwide in the first quarter of 2009. Doctors and consumers are encouraged to visit http://www.latisse.com for further product and prescribing information.

Allergan estimates global peak sales of LATISSE? could exceed $500 million per year. As the exclusive U.S. and foreign patent owner, Allergan obtains the rights to the use of bimatoprost and other prostaglandins and prostaglandin analogs as a treatment to stimulate eyelash growth.

LATISSE? Clinical Development Program

In the pivotal Phase III study, 278 healthy adult patients with no active ocular disease and with baseline minimal or moderate eyelash prominence were randomized to apply either LATISSE? or vehicle to both upper eyelid margins once daily for 16 weeks. The primary efficacy endpoint was overall eyelash prominence at the end of the 16-week treatment period as measured by a ?1-grade improvement on a 4-point Global Eyelash Assessment Scale. Secondary efficacy endpoints were eyelash length, thickness, and darkness as determined by Digital Image Analysis of patient photographs taken in a standardized manner.

All of the endpoints in the LATISSE? pivotal trial were met. By the end of the 16-week treatment period, patients treated with LATISSE? experienced statistically significant greater improvement (p < 0.0001 for each endpoint) than those in the vehicle group in the measurements of eyelash prominence, length, thickness and darkness. LATISSE? was also well tolerated with the most commonly reported adverse events being non-serious and cosmetic in nature. Common adverse events observed in the clinical trial included eye redness (3.6%), itchy eyes (3.6%) and skin hyperpigmentation (2.9%).

Important LATISSE? Safety Information

LATISSE? solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. DO NOT APPLY to the lower eyelid. If you are using LUMIGAN? or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IOP, you should only use LATISSE? under the close supervision of your doctor.

LATISSE? use may cause darkening of the eyelid skin which may be reversible. Although not reported in clinical studies, LATISSE? use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.

It is possible for hair growth to occur in other areas of your skin that LATISSE? frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using LATISSE?.

The most common side effects after using LATISSE? solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSE? solution may cause other less common side effects which typically occur on the skin close to where LATISSE? is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.

If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your doctor's advice concerning the continued use of LATISSE? solution.

Full prescribing information is available at http://www.latisse.com.

Important BOTOX? and BOTOX? Cosmetic (Botulinum Toxin Type A) Information

BOTOX? is approved for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.

BOTOX? is approved for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above.

The efficacy of BOTOX? treatment in deviations over 50 prism diopters, in restrictive strabismus, in Duane's syndrome with lateral rectus weakness, and in secondary strabismus caused by prior surgical over-recession of the antagonist has not been established. BOTOX? is ineffective in chronic paralytic strabismus except when used in conjunction with surgical repair to reduce antagonist contracture.

And BOTOX? is approved for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.

BOTOX? Cosmetic is approved for the temporary treatment of moderate to severe frown lines between the brows in people ages 18 - 65.

Important Safety Information

Who should not be treated with BOTOX? and BOTOX? Cosmetic

BOTOX? injections should not be given to people who have an infection where the physician proposes to inject. They should not be given to people who are known to be sensitive to any ingredient in the BOTOX? product.

Warnings

Serious heart problems and serious allergic reactions have been reported rarely. If you think you're having an allergic reaction or other reaction, such as difficulty swallowing, speaking, or breathing, call your doctor immediately.

Patients with certain neuromuscular disorders such as ALS, myasthenia gravis, or Lambert-Eaton syndrome may be at increased risk of serious side effects.

Patients with neuromuscular disorders may be at increased risk of clinically significant systemic effects including severe dysphagia (difficulty swallowing) and respiratory compromise from typical doses of BOTOX? and BOTOX? Cosmetic.

Dysphagia (difficulty swallowing) is a commonly reported adverse event following treatment of cervical dystonia patients with all botulinum toxins. In these patients, there are reports of rare cases of dysphagia severe enough to warrant the insertion of a gastric feeding tube.

Precautions

Patients or caregivers should be advised to seek immediate medical attention if swallowing, speech, or respiratory disorders arise.

Side Effects

Localized pain, infection, inflammation, tenderness, swelling, redness and/or bruising may be associated with the injection.

In cervical dystonia, the most common side effects following injection include difficulty swallowing (19%), upper respiratory infection (12%), neck pain (11%), and headache (11%).

In blepharospasm, the most common side effects following injection include ptosis (20.8%), inflammation of the cornea (6.3%), and eye dryness (6.3%).

In strabismus, the most common side effects following injection include ptosis (15.7%) and vertical deviation (16.9%).

In severe primary axillary hyperhidrosis, the most common side effects (3-10% of patients) include injection-site pain and bleeding, non-underarm sweating, infection, sore throat, flu, headache, fever, neck or back pain, itching and anxiety.

The most common side effects following BOTOX? Cosmetic injections include temporary eyelid droop and nausea.

Please see full product information at http://www.botox.com and http://www.botoxcosmetic.com.

Forward-Looking Statements
This press release contains "forward-looking statements," including the statements by Dr. Whitcup, Dr. Fagien and other statements regarding the safety, effectiveness, approval and market potential associated with LATISSE?, BOTOX? and BOTOX? Cosmetic. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry, biologic and pharmaceutical market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; inconsistency of treatment results among patients; potential difficulties in manufacturing; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2007 Form 10-K and subsequently filed Forms 10-Q.

About Allergan, Inc.

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential - to see more clearly, move more freely, express themselves more fully. The Company employs more than 8,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

Allergan Medical, a division of Allergan, Inc., offers the most comprehensive, science-based, aesthetic product offerings under its Total Facial Rejuvenation? portfolio, including BOTOX? Cosmetic; hyaluronic acid and collagen-based dermal fillers; and physician-dispensed skin care products. Allergan Medical also offers the industry's widest range of silicone gel-filled and saline-filled breast implant options for reconstructive and aesthetic breast surgery, and leading minimally invasive devices for obesity intervention treatment.

Source: http://guidelines-to-health-fitness.blogspot.com/2012/08/latisse-new-prescription-product.html

turbotax the bourne legacy roland martin suspended lake vostok montgomery county public schools the river dr dog